Research & Development
Aside from our generics, Upsher-Smith develops its own innovative products in inflammation, neurology and neuro-oncology.
Drug discovery of these products is conducted by our wholly owned subsidiary Proximagen, based in Cambridge, U.K.
Since Upsher-Smith acquired Proximagen in 2012, the two organizations have enjoyed a strong, synergistic relationship. Proximagen handles the front end of the R&D process, including medicinal chemistry, biology and drug metabolism and pharmacokinetics (DMPK). Then, once molecules transition into development, Upsher-Smith provides the back end, offering translational medicine; chemistry, manufacturing, controls (CMC) and formulation; and regulatory affairs and clinical operations.